Use of the helical SUPERA™ stent and Passeo-18 Lux™ drug-coated balloon to treat recurrent cephalic arch stenosis for dysfunctional brachiocephalic fistulas: 1 year results of the Arch V SUPERA-LUX study

Abstract

Background:

Aim of Arch V SUPERA-LUX was to evaluate the safety and efficacy of the combination therapy of SUPERA™ (Abbott Vascular, Santa Clara, CA, USA) helical stent implantation and Passeo-18 Lux™ (Biotronik Asia Pacific Pte Ltd, Singapore) drug coated balloon (DCB) elution to treat recurrent cephalic arch stenosis (CAS) in the setting of AV access dysfunction.

Methods:

Investigator-initiated, single-center, single-arm prospective pilot study of 20 end-stage renal failure Asian patients with a dysfunctional brachiocephalic fistula. All had symptomatic recurrent CAS within 6 months of prior intervention. The lesion was pre-dilated with a standard high-pressure balloon (Biotronik Passeo-35 HP balloon). The DCB (Passeo-18 Lux™) is subsequently inflated and the SUPERA™ stent deployed to sit 2 mm distal to the cephalic arch and covering the CAS but within the DCB zone. All patients were prescribed dual antiplatelet therapy for 3 months and followed up with Duplex ultrasound at 6- and 12-months.

Results:

There were 9 (45%) males and mean age was 67 ± 11.0 years. Mean time from prior procedure was 113 ± 68 days and main indication for reintervention was high venous pressure (9/20, 45%). Technical success was 100% and there were no peri-procedural complications related to either stent or DCB deployment. Target lesion primary patency at 6- and 12-months was 10/18 (55%) and 5/16 (31%), respectively. Mean time to target lesion re-intervention was 170 ± 82 days. Circuit access patency was 8/18 (44%) and 2/16 (13%) at 6- and 12-months respectively and mortality was 3/20 (15%) attributed to the patients’ underlying co-morbidities.

Conclusion:

Dual prong strategy of using SUPERA™ stenting and Passeo-18 Lux™ drug elution for recurrent CAS, although safe, was no more efficacious than conventional balloon angioplasty or stenting alone. Development of an intense inflammatory reaction within the stent led to reinterventions of a number of cases with suboptimal results.

Keywords

Paclitaxel coated balloon target lesion primary patency arterio-venous fistula outcome safety cephalic arch stenting

Get full access to this article

View all access options for this article.

References

Lok

Huber

Lee

, et al. KDOQI clinical practice guideline for vascular access: 2019 update. Am J Kidney Dis 2020; 75(4 Suppl 2): S1–S164.

Bennett

Hammes

Blicharski

, et al. Characterization of the cephalic arch and location of stenosis. J Vasc Access 2015; 16(1): 13–18.

Davies

Hicks

Haidar

, et al. Outcomes of intervention for cephalic arch stenosis in brachiocephalic arteriovenous fistulas. J Vasc Surg 2017; 66(5): 1504–1510.

Kim

Yoon

Woo

S-Y

, et al. Treatment strategies for cephalic arch stenosis in patients with brachiocephalic arteriovenous fistula. Ann Vasc Surg 2019; 54: 248–253.

Rajan

Clark

Patel

, et al. Prevalence and treatment of cephalic arch stenosis in dysfunctional autogenous hemodialysis fistulas. J Vasc Interv Radiol 2003; 14(5): 567–573.

Steiner

Dutta

Von Stempel

, et al. Percutaneous transluminal angioplasty in arteriovenous fistulas: current practice and future developments. J Radiol Nurs 2017; 36(3): 145–151.

Jayroe

Foley

. Arteriovenous fistula. StatPearls [Internet], 2020.

Garcia

Rosenfield

Metzger

, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv 2017; 89(7): 1259–1267.

Yin

Shi

Cui

, et al. Efficacy and safety of paclitaxel-coated balloon angioplasty for dysfunctional arteriovenous fistulas: a multicenter randomized controlled trial. Am J Kidney Dis 2021; 78(1): 19–27.

10.

Tang

Tan

Yap

, et al. Helical stent (SUPERA™) and drug-coated balloon (Passeo–18 lux™) for recurrent cephalic arch stenosis: rationale and design of arch V SUPERA–LUX study. J Vasc Access 2020; 21(4): 504–510.

11.

Rct. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018.

12.

Quencer

Arici

. Arteriovenous fistulas and their characteristic sites of stenosis. Am J Roentgenol 2015; 205(4): 726–734.

13.

Mehta

Shaikh

Chan

. Double mesh nitinol stent versus self-expanding stent-graft in recurrent/resistant cephalic vein arch stenoses in dialysis fistulae: a comparative study. Cardiovasc Intervent Radiol 2021; 44(2): 230–236.

14.

Kitrou

Katsanos

Karnabatidis

. Re: “new evidence to support the use of drug coated balloons in the treatment of dysfunctional vascular access”. Eur J Vasc Endovasc Surg 2021; 62(1): 144–151.

15.

Armstrong

Jeon-Slaughter

Kahlon

, et al. Comparative outcomes of Supera Interwoven nitinol vs bare nitinol stents for the treatment of femoropopliteal disease: insights from the XLPAD registry. J Endovasc Ther 2020; 27(1): 60–65.

16.

Miller

Preddie

Savransky

, et al. Use of the Viabahn stent graft for the treatment of recurrent cephalic arch stenosis in hemodialysis accesses. J Vasc Surg 2018; 67(2): 522–528.

17.

D’cruz

Leong

Syn

, et al. Endovascular treatment of cephalic arch stenosis in brachiocephalic arteriovenous fistulas: a systematic review and meta-analysis. J Vasc Access 2019; 20(4): 345–355.

18.

Lookstein

Haruguchi

Ouriel

, et al. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. New Engl J Med 2020; 383(8): 733–742.

19.

Kitrou

Spiliopoulos

Katsanos

, et al. Paclitaxel-coated versus plain balloon angioplasty for dysfunctional arteriovenous fistulae: one-year results of a prospective randomized controlled trial. J Vasc Interv Radiol 2015; 26(3): 348–354.

20.

Khawaja

Cassidy

Al Shakarchi

, et al. Systematic review of drug eluting balloon angioplasty for arteriovenous haemodialysis access stenosis. J Vasc Access 2016; 17(2): 103–110.

21.

Trerotola

Saad

Roy-Chaudhury

. The Lutonix AV randomized trial of paclitaxel-coated balloons in arteriovenous fistula stenosis: 2-year results and subgroup analysis. J Vasc Interv Radiol 2020; 31(1): 1–14.

22.

Therasse

Caty

Gilbert

, et al. Safety and efficacy of paclitaxel-eluting balloon angioplasty for dysfunctional hemodialysis access: a randomized trial comparing with angioplasty alone. J Vasc Interv Radiol 2021; 32(3): 350–359.e2.

23.

Lookstein

(ed.). IN.PACT AV access 6-month outcomes by lesion characteristics. In: Vascular interventional advances (VIVA), Las Vegas, Nevada, 4–7 November 2019.

24.

Vasanthamohan

Gopee-Ramanan

Athreya

. The management of cephalic arch stenosis in arteriovenous fistulas for hemodialysis: a systematic review. Cardiovasc Intervent Radiol 2015; 38(5): 1179–1185.